Novo Nordisk has scored a major trial victory after its semaglutide diabetes drug outperformed Eli Lilly’s already-marketed GLP-1 rival.

Novo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new, large trial showing the drug was able to cut body weight significantly over the ...